




PF-04929113 (SNX-5422)

Kinase Inhibitor

E1KS2656

Kinase Inhibitor Name: PF-04929113 (SNX-5422)**Catalog Number:** E1KS2656**Quantity:** 5mg**1. PHYSICAL AND CHEMICAL PROPERTIES****M.Wt:** 521.53**Formula:** C₂₅H₃₀F₃N₅O₄**Solubility:** DMSO ≥104 mg/mL Water <1 mg/mL Ethanol ≥5 mg/mL**Stability:**
2 years -20°C Powder
1 week -4°C in DMSO
1 month -80°C in DMSO**CAS No.:** 908115-27-5**Molecular Structure:****2. Biological Activity**

PF-04929113 (SNX-5422) is a potent and selective Hsp90 inhibitor with an IC₅₀ of median 50 nM. [1] Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses. PF-04929113 (SNX-5422) is a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, PF-04929113 (SNX-5422) is rapidly converted to SNX-2112, which accumulates in tumors relative to normal tissues. Inhibition of Hsp90 by SNX-2112 may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. [2] PF-04929113 (SNX-5422) is originally developed by Pfizer and Serenex, Inc., and the phase I clinical trials for PF-04929113 (SNX-5422) has been completed in the treatment of solid tumors.

3. References:

Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. Huang KH et al. J Med Chem. 2009 Jul 23;52(14):4288-305

The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.

For Research Use Only